Prospective observational study to ascertain changes in lung lung distensibility during protamine (drug) administration to reverse heparin (coagulant) and correlation with echo based right ventricular functio
Not Applicable
- Conditions
- Health Condition 1: I059- Rheumatic mitral valve disease, unspecified
- Registration Number
- CTRI/2023/06/053376
- Lead Sponsor
- DR Prabhat Tewari
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1 Age â?? From 18 Years To 60 Years
2 Gender â?? Both
3 Details â?? Patients 18-60 years old, undergoing sole mitral valve replacement, on cardiopulmonary bypass.
Exclusion Criteria
•Patients with severe Pre-op Pulmonary artery hypertension (RVSP >60 mmHg)
•Known case of Chronic obstructive pulmonary disease (COPD) and other known pulmonary disease
•Patients with h/o Balloon mitral valvotomy (BMV) or Closed mitral valvotomy (CMV)
•Patients with signs of heart failure
•Patients in atrial fibrillation, after weaning from Cardiopulmonary bypass
•Diabetic patients on insulin therapy
•Any skeletal problem involving thorax
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine changes in lung compliance during protamine administration to reverse heparin anticoagulation.Timepoint: â?¢Post intubation (baseline) <br/ ><br>â?¢Pre-protamine <br/ ><br>â?¢Every minute till 10 minutes after protamine test dose (PTD) has been administered <br/ ><br>
- Secondary Outcome Measures
Name Time Method To study the changes in Right ventricle (RV) function (FAC, TAPSE, Sâ?? & RVSP) during protamine administration, and its correlation with change in lung complianceTimepoint: â?¢Post intubation (baseline) <br/ ><br>â?¢Pre-protamine <br/ ><br>â?¢5 minutes and 10 minutes after protamine test dose (PTD) has been administered <br/ ><br>